Lorazepam challenge
Medical test for catatonia
The lorazepam challenge is a diagnostic test used in the field of psychiatry to assess the presence of catatonia, a neuropsychiatric syndrome characterized by motor, behavioral, and affective abnormalities. This test involves the administration of the benzodiazepine lorazepam to observe its effects on the patient's symptoms.
Procedure[edit | edit source]
The lorazepam challenge is typically performed in a clinical setting. The procedure involves administering a single dose of lorazepam, usually 1 to 2 mg, either orally or intravenously. The patient's response is then observed over a period of 30 minutes to 2 hours.
Indications[edit | edit source]
The test is primarily indicated for patients who exhibit signs of catatonia, which may include stupor, mutism, negativism, posturing, and waxy flexibility. Catatonia can occur in the context of various psychiatric and medical conditions, including schizophrenia, bipolar disorder, and major depressive disorder.
Interpretation[edit | edit source]
A positive response to the lorazepam challenge is characterized by a significant reduction in catatonic symptoms following the administration of the drug. This response suggests that the symptoms are indeed due to catatonia and may guide further treatment decisions, such as the use of benzodiazepines or electroconvulsive therapy (ECT).
Mechanism[edit | edit source]
Lorazepam is a benzodiazepine that acts on the gamma-aminobutyric acid (GABA) neurotransmitter system, enhancing the inhibitory effects of GABA in the brain. This action is thought to alleviate the symptoms of catatonia by modulating neural activity.
Limitations[edit | edit source]
While the lorazepam challenge can be a useful diagnostic tool, it is not definitive. Some patients with catatonia may not respond to lorazepam, and a lack of response does not rule out the diagnosis. Additionally, the test should be used with caution in patients with a history of substance abuse or benzodiazepine sensitivity.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
